Stifel Nicolaus Issues Pessimistic Forecast for Insmed (NASDAQ:INSM) Stock Price
Insmed (NASDAQ:INSM – Get Free Report) had its price objective cut by research analysts at Stifel Nicolaus from $97.00 to $96.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 18.43% from the […]
Insmed (NASDAQ:INSM – Get Free Report) had its price objective cut by research analysts at Stifel Nicolaus from $97.00 to $96.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 18.43% from the […]
